Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz

A. M. Abdelhady, Zeruesenay Desta, F. Jiang, C. W. Yeo, J. G. Shin, B. R. Overholser

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The purpose of this study was to determine the demographic and pharmacogenetic covariates that influence the disposition of efavirenz (EFV) and its major metabolites. A population pharmacokinetic (PK) model was developed from a randomized, cross-over, drug-interaction study in healthy male Korean subjects (n=17). Plasma concentrations of EFV and its hydroxy-metabolites (0-120 hours) were measured by LC/MS/MS. Genomic DNA was genotyped for variants in the cytochrome P450 (CYP) 2A6, 2B6, 3A5, and MDR1 genes. A PK model was built in a stepwise procedure using nonlinear mixed effect modeling in NONMEM 7. The covariate model was built using the generalized additive modeling and forward selection-backward elimination. Model-based simulations were performed to predict EFV steady-state concentrations following 200, 400, and 600 mg daily oral dose among different CYP2B6 genotypes. The final model included only CYP2B6 genotype as a covariate that predicts EFV clearance through the formation of 8-OH EFV that represented 65% to 80% of EFV clearance. The total clearance of EFV in CYP2B6*6/*6 genotype was ~30% lower than CYP2B6*1/ *1 or CYP2B6*1/*6 alleles (Plt;.001). Clopidogrel reduced both formation and elimination clearances of 8-OHEFV by 22% and 19%, respectively (P=.033 and .041). Other demographics and genotype of accessory CYP pathways did not predict EFV or metabolites PK. CYP2B6 genotype was the only significant predictor of EFV disposition. The developed model may serve as the foundation for further exploration of pharmacogenetic-based dosing of EFV.

Original languageEnglish
Pages (from-to)87-96
Number of pages10
JournalJournal of Clinical Pharmacology
Volume54
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

efavirenz
Pharmacogenetics
Pharmacokinetics
Population
Genotype
clopidogrel
Demography
8-hydroxyefavirenz

Keywords

  • CYP2B6
  • Efavirenz
  • Metabolites
  • Pharmacogenomics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. / Abdelhady, A. M.; Desta, Zeruesenay; Jiang, F.; Yeo, C. W.; Shin, J. G.; Overholser, B. R.

In: Journal of Clinical Pharmacology, Vol. 54, No. 1, 01.2014, p. 87-96.

Research output: Contribution to journalArticle

Abdelhady, A. M. ; Desta, Zeruesenay ; Jiang, F. ; Yeo, C. W. ; Shin, J. G. ; Overholser, B. R. / Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. In: Journal of Clinical Pharmacology. 2014 ; Vol. 54, No. 1. pp. 87-96.
@article{5c99b7a913a344029e5278c524d5bed0,
title = "Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz",
abstract = "The purpose of this study was to determine the demographic and pharmacogenetic covariates that influence the disposition of efavirenz (EFV) and its major metabolites. A population pharmacokinetic (PK) model was developed from a randomized, cross-over, drug-interaction study in healthy male Korean subjects (n=17). Plasma concentrations of EFV and its hydroxy-metabolites (0-120 hours) were measured by LC/MS/MS. Genomic DNA was genotyped for variants in the cytochrome P450 (CYP) 2A6, 2B6, 3A5, and MDR1 genes. A PK model was built in a stepwise procedure using nonlinear mixed effect modeling in NONMEM 7. The covariate model was built using the generalized additive modeling and forward selection-backward elimination. Model-based simulations were performed to predict EFV steady-state concentrations following 200, 400, and 600 mg daily oral dose among different CYP2B6 genotypes. The final model included only CYP2B6 genotype as a covariate that predicts EFV clearance through the formation of 8-OH EFV that represented 65{\%} to 80{\%} of EFV clearance. The total clearance of EFV in CYP2B6*6/*6 genotype was ~30{\%} lower than CYP2B6*1/ *1 or CYP2B6*1/*6 alleles (Plt;.001). Clopidogrel reduced both formation and elimination clearances of 8-OHEFV by 22{\%} and 19{\%}, respectively (P=.033 and .041). Other demographics and genotype of accessory CYP pathways did not predict EFV or metabolites PK. CYP2B6 genotype was the only significant predictor of EFV disposition. The developed model may serve as the foundation for further exploration of pharmacogenetic-based dosing of EFV.",
keywords = "CYP2B6, Efavirenz, Metabolites, Pharmacogenomics, Pharmacokinetics",
author = "Abdelhady, {A. M.} and Zeruesenay Desta and F. Jiang and Yeo, {C. W.} and Shin, {J. G.} and Overholser, {B. R.}",
year = "2014",
month = "1",
doi = "10.1002/jcph.208",
language = "English",
volume = "54",
pages = "87--96",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz

AU - Abdelhady, A. M.

AU - Desta, Zeruesenay

AU - Jiang, F.

AU - Yeo, C. W.

AU - Shin, J. G.

AU - Overholser, B. R.

PY - 2014/1

Y1 - 2014/1

N2 - The purpose of this study was to determine the demographic and pharmacogenetic covariates that influence the disposition of efavirenz (EFV) and its major metabolites. A population pharmacokinetic (PK) model was developed from a randomized, cross-over, drug-interaction study in healthy male Korean subjects (n=17). Plasma concentrations of EFV and its hydroxy-metabolites (0-120 hours) were measured by LC/MS/MS. Genomic DNA was genotyped for variants in the cytochrome P450 (CYP) 2A6, 2B6, 3A5, and MDR1 genes. A PK model was built in a stepwise procedure using nonlinear mixed effect modeling in NONMEM 7. The covariate model was built using the generalized additive modeling and forward selection-backward elimination. Model-based simulations were performed to predict EFV steady-state concentrations following 200, 400, and 600 mg daily oral dose among different CYP2B6 genotypes. The final model included only CYP2B6 genotype as a covariate that predicts EFV clearance through the formation of 8-OH EFV that represented 65% to 80% of EFV clearance. The total clearance of EFV in CYP2B6*6/*6 genotype was ~30% lower than CYP2B6*1/ *1 or CYP2B6*1/*6 alleles (Plt;.001). Clopidogrel reduced both formation and elimination clearances of 8-OHEFV by 22% and 19%, respectively (P=.033 and .041). Other demographics and genotype of accessory CYP pathways did not predict EFV or metabolites PK. CYP2B6 genotype was the only significant predictor of EFV disposition. The developed model may serve as the foundation for further exploration of pharmacogenetic-based dosing of EFV.

AB - The purpose of this study was to determine the demographic and pharmacogenetic covariates that influence the disposition of efavirenz (EFV) and its major metabolites. A population pharmacokinetic (PK) model was developed from a randomized, cross-over, drug-interaction study in healthy male Korean subjects (n=17). Plasma concentrations of EFV and its hydroxy-metabolites (0-120 hours) were measured by LC/MS/MS. Genomic DNA was genotyped for variants in the cytochrome P450 (CYP) 2A6, 2B6, 3A5, and MDR1 genes. A PK model was built in a stepwise procedure using nonlinear mixed effect modeling in NONMEM 7. The covariate model was built using the generalized additive modeling and forward selection-backward elimination. Model-based simulations were performed to predict EFV steady-state concentrations following 200, 400, and 600 mg daily oral dose among different CYP2B6 genotypes. The final model included only CYP2B6 genotype as a covariate that predicts EFV clearance through the formation of 8-OH EFV that represented 65% to 80% of EFV clearance. The total clearance of EFV in CYP2B6*6/*6 genotype was ~30% lower than CYP2B6*1/ *1 or CYP2B6*1/*6 alleles (Plt;.001). Clopidogrel reduced both formation and elimination clearances of 8-OHEFV by 22% and 19%, respectively (P=.033 and .041). Other demographics and genotype of accessory CYP pathways did not predict EFV or metabolites PK. CYP2B6 genotype was the only significant predictor of EFV disposition. The developed model may serve as the foundation for further exploration of pharmacogenetic-based dosing of EFV.

KW - CYP2B6

KW - Efavirenz

KW - Metabolites

KW - Pharmacogenomics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84893316481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893316481&partnerID=8YFLogxK

U2 - 10.1002/jcph.208

DO - 10.1002/jcph.208

M3 - Article

C2 - 24142869

AN - SCOPUS:84893316481

VL - 54

SP - 87

EP - 96

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 1

ER -